Compass Pathways plc (Nasdaq: CMPS) released 26-week results from its second Phase 3 clinical trial, COMP006, of COMP360, a synthetic ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA

Wolfe Research on Compass Pathways (CMPS): 'we expect the stock to regain strong momentum after this pullback'July 7, 2026 3:52 PM Oppenheimer on Compass Pathways (CMPS): 'Reinforced Durability Strengthens Launch Prospects'July 7, 2026 12:11 PM Compass Pathways (CMPS) PT Raised to $25 at BTIG, 'executed nearly flawlessly on everything within its control'July 7, 2026 12:10 PM